Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease

Torsten Falk, Xu Yue, Shiling Zhang, Alexander D. McCourt, Brandon J. Yee, Robert T. Gonzalez, Scott J. Sherman

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Developing novel neuroprotective strategies for the treatment of Parkinson's disease (PD) is of great importance. We have previously shown that vascular endothelial growth factor-B (VEGF-B) is up-regulated in an in vitro model of PD using the neurotoxin rotenone. Addition of exogenous VEGF-B167 was neuroprotective in this same model, suggesting that VEGF-B is a natural response to neurodegenerative challenges. Now we have extended this research using in vivo experiments. We tested a single intra-striatal injection of 3μg VEGF-B186, the more diffusible VEGF-B isoform, in a mild progressive unilateral 6-hydroxydopamine (6-OHDA) rat in vivo PD model. Treatment with VEGF-B186 6h prior to lesioning with 6-OHDA improved amphetamine-induced rotations and forepaw preference at 2, 4 and 6 weeks post-injection, indicating a neuroprotective effect. Immunohistochemical analysis showed that VEGF-B186 treatment partially protected dopaminergic fibers in the striatum and demonstrated a partial rescue of the dopaminergic neurons in the caudal sub-region of the substantia nigra. Altogether our data suggest that VEGF-B186 could be a new candidate trophic factor for the treatment of PD.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalNeuroscience Letters
Volume496
Issue number1
DOIs
StatePublished - May 27 2011

Keywords

  • 6-OHDA lesion
  • Midbrain culture
  • Neurotrophic therapy
  • VEGF-B167
  • VEGF-B186

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease'. Together they form a unique fingerprint.

Cite this